Nofetumomab

N/A

Report date: 2025/11/24 11:49:36

Base Information

Drug NameNofetumomab
Drug Alias Name若莫单抗F(ab)2 NRLU10 technetium (Tc 99m)OncoTrac SCLC诺非单抗Technetium (99mTc) nofetumomab merpentan +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[6] 
Mechanisms of ActionAnti-carcinoma associated antigenSingle-photon emission-computed tomography enhancers
TargetsCarcinoma associated antigen
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsSmall Cell Lung Carcinoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1996/08/20
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG